At week 48 , ACR50 and ACR70 responses were demonstrated in 18 % and 3 % of patients , respectively , who continued taking anakinra ( all dose groups ) and in 20 % and 1 % of patients , respectively , who were originally receiving placebo and then were randomized to all doses of anakinra .
